Last reviewed · How we verify

CHF 1535 100/6 pMDI 2 months

Chiesi Farmaceutici S.p.A. · Phase 3 active Small molecule

CHF 1535 100/6 pMDI 2 months is a ICS/LABA combination Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Foster®.

CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.

CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameCHF 1535 100/6 pMDI 2 months
Also known asFoster®
SponsorChiesi Farmaceutici S.p.A.
Drug classICS/LABA combination
TargetGlucocorticoid receptor (ICS component); Beta-2 adrenergic receptor (LABA component)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

The formulation combines an inhaled corticosteroid (ICS) component that suppresses airway inflammation and a long-acting beta-2 agonist (LABA) that provides sustained bronchodilation. Delivered via pressurized metered-dose inhaler (pMDI), this combination therapy addresses both inflammatory and obstructive components of chronic respiratory conditions, improving airflow and reducing exacerbations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CHF 1535 100/6 pMDI 2 months

What is CHF 1535 100/6 pMDI 2 months?

CHF 1535 100/6 pMDI 2 months is a ICS/LABA combination drug developed by Chiesi Farmaceutici S.p.A., indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does CHF 1535 100/6 pMDI 2 months work?

CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.

What is CHF 1535 100/6 pMDI 2 months used for?

CHF 1535 100/6 pMDI 2 months is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes CHF 1535 100/6 pMDI 2 months?

CHF 1535 100/6 pMDI 2 months is developed by Chiesi Farmaceutici S.p.A. (see full Chiesi Farmaceutici S.p.A. pipeline at /company/chiesi-farmaceutici-s-p-a).

Is CHF 1535 100/6 pMDI 2 months also known as anything else?

CHF 1535 100/6 pMDI 2 months is also known as Foster®.

What drug class is CHF 1535 100/6 pMDI 2 months in?

CHF 1535 100/6 pMDI 2 months belongs to the ICS/LABA combination class. See all ICS/LABA combination drugs at /class/ics-laba-combination.

What development phase is CHF 1535 100/6 pMDI 2 months in?

CHF 1535 100/6 pMDI 2 months is in Phase 3.

What are the side effects of CHF 1535 100/6 pMDI 2 months?

Common side effects of CHF 1535 100/6 pMDI 2 months include Tremor, Headache, Palpitations, Oral candidiasis, Nervousness.

What does CHF 1535 100/6 pMDI 2 months target?

CHF 1535 100/6 pMDI 2 months targets Glucocorticoid receptor (ICS component); Beta-2 adrenergic receptor (LABA component) and is a ICS/LABA combination.

Related